Horn Margaret A 4

What Happened

• Margaret A. Horn, Chief Operating Officer of Revolution Medicines (RVMD), exercised a total of 10,000 option shares on June 11, 2026 (1,094 shares at $42.45 and 8,906 shares at $40.74), paying about $409,270 in exercise price. She then sold 10,000 shares in open-market transactions the same day for total gross proceeds of approximately $1,480,139 (weighted average ≈ $148.01/share). The transactions were reported on Form 4 filed June 15, 2026.

Key Details

• Transaction date: June 11, 2026; Form 4 filed June 15, 2026 (timely — filed within the 2 business‑day window).
• Exercise details: 1,094 shares @ $42.45 (cost $46,440) and 8,906 shares @ $40.74 (cost $362,830).
• Sales: 10,000 shares sold in multiple block trades at weighted average prices shown per lot (individual trade ranges are disclosed in the footnotes); total proceeds ≈ $1,480,139.
• Net (gross proceeds minus exercise cost): roughly $1.07M before taxes, fees or other withholdings.
• Notable footnotes: trades were executed pursuant to a 10b5‑1 trading plan adopted March 12, 2026 (F1). Filing also references 73,050 restricted stock units (F2) and 652 shares from the Employee Stock Purchase Plan (F3). Vesting schedule for the option is monthly over 48 months from March 1, 2025 (F10).
• Shares owned after transaction: not specified in the provided filing excerpt.

Context

• Coding: "M" entries reflect option exercise/conversion; the immediate open-market "S" sales indicate the exercised shares were sold on the same day (a common cash-out of exercised options). Two $0.00 “Disposed” derivative lines reflect reporting of the exercised/converted derivative shares that were subsequently sold.
• Interpretation for investors: this is a planned, pre-arranged sell under a 10b5‑1 program (routine liquidity), not necessarily a directional signal about company fundamentals. Purchases generally carry more bullish weight than routine sales; here Horn paid to exercise options and realized proceeds by selling the resulting shares.